Revenue and Expenses - Revenue for the year ended December 31, 2025 was approximately $65,000, a decrease of 52% compared to $135,000 in 2024[145] - Cost of revenue increased to approximately $321,000 in 2025 from $123,000 in 2024, reflecting a significant rise in expenses[146] - Operating expenses totaled approximately $20.9 million in 2025, up from $19.3 million in 2024, marking an increase of approximately 8%[147] - Research and development expenses rose to approximately $12.3 million in 2025, an increase of approximately $1.3 million, or 12%, compared to $11.0 million in 2024[149] - General and administrative expenses increased to approximately $7.8 million in 2025, up by approximately $540,000, or 7%, from $7.3 million in 2024[150] - Selling and marketing expenses decreased to approximately $758,000 in 2025, down by approximately $295,000, or 28%, from $1.1 million in 2024[151] Financial Position - As of December 31, 2025, cash and cash equivalents were approximately $19.2 million, with working capital of approximately $17.6 million[155] - The company incurred a net loss of approximately $20.2 million for the year ended December 31, 2025[155] Cash Flow Activities - Net cash provided in investing activities for the year ended December 31, 2025 was approximately $951,000, primarily from the maturity of short-term available-for-sale investments[160] - Net cash provided by financing activities for the year ended December 31, 2025 was approximately $7.4 million, mainly from net proceeds from the ATM Facility[161] - Net cash provided by financing activities for the year ended December 31, 2024 was approximately $20.3 million, primarily from net proceeds from the ATM Facility[162] Stock and Compensation - The company has stock-based compensation programs including RSAs, RSUs, and stock options, with fair value determined at the grant date and amortized over the vesting period[165] - The fair value of performance-based restricted stock units is fixed at the grant date using a Monte Carlo simulation[165] - The company’s stock option awards are valued using the Black-Scholes Option Pricing Model[165] Dividends and Interest - The expected dividend rate is 0% as the company has not declared or paid dividends and has no plans to do so[167] - Interest income for 2025 was approximately $931,000, an increase of approximately $152,000, or 20%, compared to $779,000 in 2024[152] Accounting Policies - The company’s financial statements are prepared in accordance with U.S. generally accepted accounting principles, requiring judgment in making estimates and assumptions[163] - Lease liabilities and ROU assets are recognized for all leases greater than 12 months based on the present value of lease payments[164] - The risk-free interest rate for stock awards is based on U.S. Treasury securities yields with maturities similar to the expected terms of the awards[167] Capital Raising - The company closed a registered direct offering on February 24, 2026, raising approximately $23.6 million in net proceeds from the sale of 5,000,000 shares at $5.00 per share[155]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 27, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to __________ Commission file number: 1-14092 THE BOSTON BEER COMPANY, INC. (Exact name of registrant as specified in its charter) Massachusetts 04-32 ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______________ to _______________ 2560 General Armistead Avenue, Audubon, PA 19403-5214 (610) 930-1800 Commission File No. 001-35621 GLOBUS MEDICAL, INC. (Exact name of regis ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) 000-31311 (Commission file number) PDF SOLUTIONS, INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of (I.R.S. Employer Incorporation or organization) Identification No.) 2858 De La Cruz Blvd. 95050 Santa Clara, California (Zip Code) (Address of Registrant's principal executive of ices) (408) 280-7900 (Registrant's telephone number, including area code) Securi ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number: 001-35558 CARDIFF ONCOLOGY, INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or or ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 e FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED December 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NUMBER 001-39447 CCC Intelligent Solutions Holdings Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0-25965 ZIFF DAVIS, INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) (I.R ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to __________ Commission File Number: 001-40465 Marqeta, Inc. (Exact name of registrant as specified in its charter) Delaware 27-4306690 (State or other ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-03970 ENVIRI CORPORATION (Exact name of registrant as specified in its charter) Delaware 23-1483991 (State or other jurisdiction of incorporation or organization) (I.R.S. employe ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______________ to _______________ Commission file number 001-37362 Black Stone Minerals, L.P. (Exact Name of Registrant As Specified in its charter) Delaware 47-18466 ...